Cambridge, UK and Indianapolis, US – 14 September 2018: Acacia
Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of Yupelri (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Sept. 11, 2018 /PRNewswire/
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),
Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company
Otonomy Initiates Phase 3 Clinical Trial of Otividex in Ménière’s Disease
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) — Otonomy, Inc.
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE) July 12, 2018 –Vaxart, Inc.